Enduring remission of active and sight-threatening Graves' orbitopathy with rituximab: report of two cases.
In conclusion, rituximab may be an effective second-line therapy in GO patients, providing long-lasting remission.
PMID: 29937466 [PubMed - as supplied by publisher]
Source: Endocrine Journal - Category: Endocrinology Tags: Endocr J Source Type: research
More News: Cancer & Oncology | Carcinoma | Endocrinology | Eyes | Hypermetropia (long sighted) | Laboratory Medicine | Methylprednisolone | Rituxan | Smokers | Study | Thyroid | Thyroid Cancer | Thyroidectomy